Pharmaceutical Costs

Unrelenting and unpredictable increases in prescription drug prices have spurred states to try to unlock the black box of manufacturer pricing strategies by requiring disclosure of how prices are set and how rebates are handled throughout the supply chain. Six states already have transparency laws on their books and almost two dozen more have introduced […]

Read More
  • State Health Policy Blog
    Deadline Looms for State Comments on Fed’s Latest Insurance Rules

    Deadline Looms for State Comments on Fed’s Latest Insurance Rules

    After a delay, the Department of Health and Human Services (HHS) has issued its proposed annual rule regulating state health insurance markets, including coverage sold through the Affordable Care Act (ACA) marketplaces. View NASHP’s chart highlighting the rule’s provisions that impact states here. The deadline to submit comments on the rule is Feb. 19, 2019. […]

    Read More
  • State Health Policy Blog
    New Tools Help States Document Rx Costs and Identify Potential Savings

    New Tools Help States Document Rx Costs and Identify Potential Savings

    Just how much are states spending on prescription drugs? And, which drugs account for their greatest expense? As state policymakers grapple with solutions to the problem of rising drug costs, officials are performing research to  provide critical evidence and tools needed to inform policy. Two recent state efforts to document their prescription drug costs may […]

    Read More
  • State Health Policy Blog
    As State Legislatures Convene, Lawmakers Quickly Submit Bills to Curb Prescription Prices

    As State Legislatures Convene, Lawmakers Quickly Submit Bills to Curb Prescription Prices

    One week into the 2019 legislative season, lawmakers from 11 states have already submitted 30 bills to address the rising cost of prescription drugs. The bills submitted to date seek to implement wholesale drug importation programs, increase pharmaceutical pricing transparency, and regulate pharmacy benefit managers (PBMs), along with other drug cost containment initiatives. Last year, […]

    Read More
  • State Health Policy Blog
    Twenty-Eight States Passed 45 Bills to Curb Rising Rx Drug Costs in the Short 2018 Legislative Session

    Twenty-Eight States Passed 45 Bills to Curb Rising Rx Drug Costs in the Short 2018 Legislative Session

    *Updated Oct. 15, 2018 Despite a short legislative season, state lawmakers across the country introduced an unprecedented 174 bills to stem the rising cost of prescription drugs and have enacted 45 into law — with seven state legislatures still in session. Last year, state legislatures introduced 100 Rx cost control bills and passed 27. Register […]

    Read More
  • A Glossary of All Terms Pharma

    A Glossary of All Terms Pharma

    If you’re working to control the cost of prescription drugs, you need to know the lingo used by the pharmaceutical industry. Below is a glossary of terms commonly used by players in the drug research, regulation, manufacturing, distribution, and purchasing worlds. Drug Product Terms Brand product: Branded products are not generic drugs or products. A brand can be […]

    Read More
  • State Health Policy Blog
    While the Administration Mulls How to Curb Prescription Costs, State Legislatures Take the Lead

    While the Administration Mulls How to Curb Prescription Costs, State Legislatures Take the Lead

    As the country awaits the Administration’s plan to curb Rx drug costs, states take the lead, proposing and passing legislation to lower costs, despite industry opposition. As we await the details of President Trump’s proposals to curb escalating drug prices, states are continuing to push legislation to lower the cost of prescription drugs, despite the strong […]

    Read More
  • State Health Policy Blog
    States’ Prescription Drug Transparency Laws Open the Black Box of Drug Pricing

    States’ Prescription Drug Transparency Laws Open the Black Box of Drug Pricing

    Several states have passed drug price transparency laws that require drug makers to report the reasons behind dramatic price increases. These laws are an important first step to shine a light on why drug prices are rapidly climbing. To address a problem, state health policymakers need to understand it, but transparency laws don’t yet give […]

    Read More
  • Publications
    Legal Challenges of Rx Drug Laws Passed in 2017 Will Shape States’ Future Cost Containment Legislation

    Legal Challenges of Rx Drug Laws Passed in 2017 Will Shape States’ Future Cost Containment Legislation

    As the number of state bills to rein in prescription drug prices grows beyond 150 nationwide in 2018, the first generation of several state laws passed last year are now before the courts. The pharmaceutical industry has consistently challenged drug cost transparency and price gouging legislation passed in 2017 in federal courts. How well these […]

    Read More
  • An Oregon State Lawmaker Crafts a Winning Strategy for Transparency Legislation

    An Oregon State Lawmaker Crafts a Winning Strategy for Transparency Legislation

    Last week, Oregon Gov. Kate Brown signed a drug cost transparency bill into law that requires drug makers to report the reasons behind dramatic drug price increases. The bill’s leading advocate and architect, state Rep. Robert Nosse, D-Portland, worked for nearly three years to create a prescription cost containment bill that would win bipartisan support […]

    Read More